The company will resume the Phase II trial, initially at a lower dose and with a new immunomodulatory regimen.

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...

The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

The firm will evaluate its EGFR-targeted ADC ALX2004 in advanced non-small cell lung, head and neck, esophageal, and colorectal cancers.

Precigen had sought accelerated approval for Papzimeos, but the FDA opted to grant it full approval after reviewing data from a Phase I/II trial.

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.